Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

593
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
593
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

351
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
351
Angina IV: Management01:26

Angina IV: Management

435
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
435
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

863
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
863

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.

The lancet. Diabetes & endocrinology·2017
Same author

The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study.

Atherosclerosis·2017
Same author

Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study.

Nutrition (Burbank, Los Angeles County, Calif.)·2017
Same author

A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience.

Journal of clinical lipidology·2017
Same author

The Upregulation of Integrin α<sub>D</sub>β<sub>2</sub> (CD11d/CD18) on Inflammatory Macrophages Promotes Macrophage Retention in Vascular Lesions and Development of Atherosclerosis.

Journal of immunology (Baltimore, Md. : 1950)·2017
Same author

Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia.

Nature reviews. Cardiology·2017

Related Experiment Video

Updated: Apr 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria.

Salim S Virani1, Julia M Akeroyd2, Vijay Nambi3

  • 1Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for Innovations, Houston, Tex; Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Tex; Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Tex; Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Tex; Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, Tex.

The American Journal of Medicine
|June 15, 2015
PubMed
Summary

The IMPROVE-IT trial showed simvastatin/ezetimibe reduced cardiovascular events in acute coronary syndrome (ACS) patients. However, only 31.6% of ACS patients met strict criteria, suggesting broader ezetimibe use potential.

Keywords:
EzetimibeIMPROVE-ITModerate- to high-intensity statin therapyTreatment practice

More Related Videos

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

802

Related Experiment Videos

Last Updated: Apr 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

802

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) demonstrated a 6% relative risk reduction in cardiovascular events with simvastatin/ezetimibe versus simvastatin alone in acute coronary syndrome (ACS) patients.
  • Strict inclusion criteria (LDL-C 50-125 mg/dL, no statins > simvastatin 40 mg) limit the generalizability of IMPROVE-IT findings to routine ACS care.

Purpose of the Study:

  • To assess the proportion of acute coronary syndrome patients in a large healthcare system eligible for ezetimibe based on IMPROVE-IT criteria.
  • To evaluate the potential for increased ezetimibe use if IMPROVE-IT criteria are not strictly adhered to.

Main Methods:

  • Retrospective analysis of 219,625 acute coronary syndrome patients from the Veterans Affairs healthcare system over 5 years.
  • Determined eligibility for ezetimibe based on strict IMPROVE-IT criteria.
  • Assessed potential for expanded ezetimibe use in patients not meeting criteria due to potent statin use, statin intolerance, or elevated LDL-C.

Main Results:

  • Only 31.6% (69,508/219,625) of ACS patients met the strict IMPROVE-IT eligibility criteria for ezetimibe.
  • Among patients not meeting criteria, an additional 28% could potentially receive ezetimibe with statins more potent than simvastatin 40 mg.
  • Further potential for ezetimibe use was identified in 7.1% with statin intolerance and 10.4% with LDL-C >125 mg/dL.

Conclusions:

  • This study provides initial insights into the real-world implications of the IMPROVE-IT trial in a large healthcare system.
  • While 31.6% of ACS patients meet strict criteria, a significant proportion could benefit from ezetimibe outside these parameters.
  • Findings necessitate a discussion regarding ezetimibe's role in ACS patients on high-intensity statins or with statin intolerance.